J&J Sues HHS Over 340B Hospital Drug-discount Program
3M, UnitedHealth Share Losses Lead Dow's 115-Point Drop
Express News | Johnson & Johnson Medtech Receives Ide Approval for Ottava™ Robotic Surgical System
Johnson & Johnson (JNJ.US) nicastrin monoclonal antibody injection is planned to be included in priority review.
On November 12th, the official website of CDE announced that Johnson & Johnson (JNJ.US) nicalizumab injection is expected to be included in the priority review.
Johnson & Johnson Today Announces That The U.S. FDA Has Granted Nipocalimab Breakthrough Therapy Designation For The Treatment Of Adults Living With Moderate-To-Severe Sjögren's Disease, A Debilitating And Chronic Autoantibody Disease With High...
Express News | Nipocalimab Is the First and Only Investigational Therapy Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults Living With Moderate-to-Severe Sjögren's Disease